Phase 2 Study of AFM13 in Combination With AB-101 in Subjects With R/R HL and CD30+ PTCL
Status:
Not yet recruiting
Trial end date:
2027-11-30
Target enrollment:
Participant gender:
Summary
AFM13-203 is a phase 2, open-label, multi-center, multi-cohort study with a safety run-in
followed by expansion cohorts. The study is evaluating the safety and efficacy of AFM13 in
combination with AB-101 in subjects with R/R classical HL and CD30-positive PTCL.